Your browser doesn't support javascript.
loading
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki, Kensuke; Ohtake, Shigeki; Honda, Sumihisa; Matsuda, Mitsuhiro; Wakita, Atsushi; Nawa, Yuichiro; Takase, Ken; Maeda, Akio; Sezaki, Nobuo; Yokoyama, Hisayuki; Takada, Satoru; Hirano, Daiki; Tomikawa, Tatsuki; Sumi, Masahiko; Yano, Shingo; Handa, Hiroshi; Ota, Shuichi; Fujita, Hiroyuki; Fujimaki, Katsumichi; Mugitani, Atsuko; Kojima, Kensuke; Kajiguchi, Tomohiro; Fujimoto, Ko; Asou, Norio; Usui, Noriko; Ishikawa, Yuichi; Katsumi, Akira; Matsumura, Itaru; Kiyoi, Hitoshi; Miyazaki, Yasushi.
Afiliación
  • Usuki K; Department of Hematology, NTT Medical Center Tokyo, Higashi-Gotanda 5-9-22, Shinagawa-Ku, Tokyo, 141-8625, Japan. kensuke.usuki@gmail.com.
  • Ohtake S; Kanazawa University, Kanazawa, Japan.
  • Honda S; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Matsuda M; PL General Hospital, Tondabayashi, Osaka, Japan.
  • Wakita A; Nagoya City University East Medical Center, Nagoya, Japan.
  • Nawa Y; Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Takase K; Kyushu Medical Center, Fukuoka, Japan.
  • Maeda A; Hyogo Cancer Center, Akashi, Japan.
  • Sezaki N; Chugoku Central Hospital, Fukuyama, Japan.
  • Yokoyama H; National Hospital Organization Sendai Medical Center, Sendai, Japan.
  • Takada S; Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Hirano D; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Tomikawa T; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
  • Sumi M; Nagano Red Cross Hospital, Nagano, Japan.
  • Yano S; Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
  • Handa H; Gunma University, Maebashi, Japan.
  • Ota S; Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Fujita H; Department of Hematology, Yokohama Nanbu Hospital, Yokohama, Japan.
  • Fujimaki K; Department of Hematology, Fujisawa City Hospital, Kanagawa, Japan.
  • Mugitani A; Division of Hematology, Fuchu Hospital, Osaka, Japan.
  • Kojima K; Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Japan.
  • Kajiguchi T; Department of Hematology and Oncology, Tosei General Hospital, Seto, Japan.
  • Fujimoto K; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
  • Asou N; International Medical Center, Saitama Medical University, Hidaka, Japan.
  • Usui N; Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan.
  • Ishikawa Y; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Katsumi A; Department of Hematology, National Center for Geriatrics and Gerontology, Obu, Japan.
  • Matsumura I; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
  • Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Miyazaki Y; Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Int J Hematol ; 119(1): 24-38, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38015362
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58.9% [95% CI: 54.5-63.1%] vs 35.5% [33.3-37.8%], p < 0.0001). Women had a higher OS rate than men (5-year OS, 34% [95% CI; 31.4-36.7%] vs 27.7% [25.7-29.7%], p < 0.0001). The OS rate was lower in patients aged 40 and older than those under 40, and even lower in those over 65 (5-year OS for ages < 40, 40-64, 65-74, ≥ 75: 74.5% [95% CI; 69.3-79.0%] vs 47.5% [44.4-50.6%] vs 19.3% [16.8-22.0%] vs 7.3% [5.5-9.4%], respectively). This is the first paper to present large-scale data on survival and clinical characteristics in Japanese AML patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mielomonocítica Crónica / Leucemia Mieloide Aguda Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mielomonocítica Crónica / Leucemia Mieloide Aguda Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón